أرسل هذا في رسالة قصيرة: Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC

  _____    __   __    _____      ___      ______  
 /  ___||  \ \\/ //  / ____||   / _ \\   /_____// 
| // __     \ ` //  / //---`'  / //\ \\  `____ `  
| \\_\ ||    | ||   \ \\___   |  ___  || /___//   
 \____//     |_||    \_____|| |_||  |_|| `__ `    
  `---`      `-`'     `----`  `-`   `-`  /_//     
                                         `-`